HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Thyroid cancer treatment no longer ‘one-size-fits-all’ approach
-
- From research funding to drug pricing: 12 questions to ask your political candidates John Sweetenham, MD, FRCP, FACP; Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- FDA approves imaging agent to detect spread of head and neck cancers
- Cervical cancer incidence highest among women outside screening parameters
- Postoperative radiation, lymph node dissection shows promise in lymph-node positive patients with pancreatic cancer
- Stereotactic radiosurgery controlled CNS metastases in renal cell carcinoma
- HPV, p16 status predicted outcomes in recurrent, metastatic SCCHN
- Addition of bevacizumab to chemotherapy improved QOL in ovarian cancer
- Aggressive management of iron-deficiency anemia required to reduce sudden sensorineural hearing loss
-
- LMWH prevented recurrent placenta-mediated pregnancy complications
- Motesanib plus carboplatin, paclitaxel extended survival in NSCLC
- Nonmelanoma skin cancer increased subsequent primary cancer risk
- Prophylaxis reduced risk for chemotherapy-related infection in pediatric ALL, AML
- Blinatumomab shows promise in relapsed, refractory ALL
- Breast cancer susceptibility panel testing rarely found actionable mutations
- Continuous treatment ‘essential’ for patients with newly diagnosed myeloma
- Nivolumab conferred long-term survival in advanced melanoma
-
- Patient demands not a factor in inappropriate tests, treatments
- Adjuvant ipilimumab improved RFS in high-risk, stage III melanoma
- Early docetaxel with ADT extended OS in metastatic prostate cancer
- First-line bevacizumab, cetuximab equally effective for metastatic colorectal cancer
- Novel PD-L1 antibody demonstrated activity in metastatic urothelial bladder cancer
- ALTTO: Lapatinib did not improve outcomes for early-stage, HER-2–positive breast cancer
- Ponatinib shows promise for advanced gastrointestinal stromal tumors
- Discontinuation of statin use near end of life improved QOL
-